Predictors of osteoclast activity in patients with sickle cell disease

Haematologica

Volumn 96, Issue 8, 2011, Pages 1092-1098

  Nouraie, Mehdi ^a   Cheng, Kevin ^a   Niu, Xiaomei ^a   Moore King, Evadne ^a   Fadojutimi Akinsi, Margaret F ^a   Minniti, Caterina P ^b   Sable, Craig ^c   Rana, Sohail ^a   Dham, Niti ^c   Campbell, Andrew ^d   Ensing, Gregory ^d   Kato, Gregory J ^b   Gladwin, Mark T ^e   Castro, Oswaldo L ^a   Gordeuk, Victor R ^a  

^a HOWARD UNIVERSITY   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Bone turnover; Inflammation; Osteoclast activity; Pulmonary complications; Sickle cell disease; TRACP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; FERRITIN; INTERLEUKIN 8; NITROGEN; RANTES; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; UREA;

ADULT; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; HEMODYNAMIC PARAMETERS; HUMAN; IRON OVERLOAD; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; OSTEOCLAST ACTIVITY; PREDICTIVE VALUE; SICKLE CELL ANEMIA; TARTRATE RESISTANT ACID PHOSPHATASE 5B BLOOD LEVEL; TRICUSPID REGURGITATION VELOCITY; UREA NITROGEN BLOOD LEVEL;

ACID PHOSPHATASE; ADULT; ANEMIA, SICKLE CELL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; OSTEOCLASTS; REFERENCE VALUES;

EID: 79961077761     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.042499     Document Type: Article

References (52)

1. Buchowski MS, de la Fuente FA, Flakoll PJ, Chen KY, Turner EA. Increased bone turnover is associated with protein and energy metabolism in adolescents with sickle cell anemia. Am J Physiol Endocrinol Metab. 2001;280(3):E518-27.
2. Dresner Pollack R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol. 2000;111(3):902-7.
3. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol. 2004;127(2):127-39.
4. Fung EB, Kawchak DA, Zemel BS, Rovner AJ, Ohene-Frempong K, Stallings VA. Markers of bone turnover are associated with growth and development in young subjects with sickle cell anemia. Pediatr Blood Cancer. 2008;50(3):620-3.
5. Serarslan Y, Kalaci A, Ozkan C, Dogramaci Y, Cokluk C, Yanat AN. Morphometry of the thoracolumbar vertebrae in sickle cell disease. J Clin Neurosci. 2010;17(2):182-6.
6. Isomura H, Fujie K, Shibata K, Inoue N, Iizuka T, Takebe G, et al. Bone metabolism and oxidative stress in postmenopausal rats with iron overload. Toxicology. 2004;197 (2):93-100.
7. Kudo H, Suzuki S, Watanabe A, Kikuchi H, Sassa S, Sakamoto S. Effects of colloidal iron overload on renal and hepatic siderosis and the femur in male rats. Toxicology. 2008;246(2-3):143-7.
8. Ishii KA, Fumoto T, Iwai K, Takeshita S, Ito M, Shimohata N, et al. Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med. 2009;15(3): 259-66.
9. Yamasaki K, Hagiwara H. Excess iron inhibits osteoblast metabolism. Toxicol Lett. 2009;191(2-3):211-5.
10. Zarjou A, Jeney V, Arosio P, Poli M, Zavaczki E, Balla G, Balla J. Ferritin ferroxidase activity: a potent inhibitor of osteogenesis. J Bone Miner Res. 2010;25(1):164-72.
11. Tsay J, Yang Z, Ross FP, CunninghamRundles S, Lin H, Coleman R, et al. Bone loss due to iron overload in a murine model: importance of oxidative stress. Blood. 2010;116(14):2582-9.
12. Lord DK, Cross NC, Bevilacqua MA, Rider SH, Gorman PA, Groves AV, et al. Type 5 acid phosphatase. Sequence, expression and chromosomal localization of a differentiation- associated protein of the human macrophage. Eur J Biochem. 1990;189(2): 287-93.
13. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Vaananen HK. Tartrateresistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab. 2006;52(9-10):499-509.
14. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem. 2001;47(1):74-80.
15. Kawaguchi T, Nakano T, Sasagawa K, Ohashi T, Miura T, Komoda T. Tartrateresistant acid phosphatase 5a and 5b contain distinct sugar moieties. Clin Biochem. 2008;41(14-15):1245-9.
16. Janckila AJ, Yam LT. Biology and clinical significance of tartrate-resistant acid phosphatases: new perspectives on an old enzyme. Calcif Tissue Int. 2009;85(6):465-483.
17. Voskaridou E, Stoupa E, Antoniadou L, Pre - metis E, Konstantopoulos K, Papassotiriou I, Terpos E. Osteoporosis and osteosclerosis in sickle cell/beta-thalassemia: the role of the RANKL/osteoprotegerin axis. Haema - tolo gica. 2006;91(6): 813-6.
18. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Goldsmith JC, Woolson R, et al. Safety and efficacy of sildenafil therapy for Doppler-defined pulmonary hypertension in patients with sickle cell disease: preliminary results of the walk-PHaSST clinical trial. ASH Annual Meeting. Blood. 2009; 114:571.
19. Niu X, Nouraie M, Campbell A, Rana S, Minniti CP, Sable C, et al. Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PLoS One. 2009;4(11): e7956.
20. Sarrai M, Duroseau H, D'Augustine J, Moktan S, Bellevue R. Bone mass density in adults with sickle cell disease. Br J Haematol. 2007;136(4):666-72.
21. Miller RG, Segal JB, Ashar BH, Leung S, Ahmed S, Siddique S, et al. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol. 2006;81(4):236-41.
22. Gurevitch O, Slavin S. The hematological etiology of osteoporosis. Med Hypotheses. 2006;67(4):729-35.
23. Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with beta thalassemia major. Bone. 2011;48(3):425-32.
24. Guggenbuhl P, Deugnier Y, Boisdet JF, Rolland Y, Perdriger A, Pawlotsky Y, Chales G. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int. 2005;16(12): 1809-14.
25. Sadat-Ali M, Sultan O, Al-Turki H, Alelq A. Does high serum iron level induce low bone mass in sickle cell anemia? Biometals. 2011;24(1):19-22.
26. Karimi M, Ghiam AF, Hashemi A, Alinejad S, Soweid M, Kashef S. Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatr. 2007;44(1):29-32.
27. Kyriakou A, Savva SC, Savvides I, Pangalou E, Ioannou YS, Christou S, Skordis N. Gender differences in the prevalence and severity of bone disease in thalassaemia. Pediatr Endocrinol Rev 2008;6(Suppl 1): 116-22.
28. Lal A, Fung EB, Pakbaz Z, Hackney- Stephens E, Vichinsky EP. Bone mineral density in children with sickle cell anemia. Pediatr Blood Cancer. 2006;47(7):901-6.
29. Vogiatzi MG, Autio KA, Schneider R, Giardina PJ. Low bone mass in prepubertal children with thalassemia major: insights into the pathogenesis of low bone mass in thalassemia. J Pediatr Endocrinol Metab. 2004;17(10):1415-21.
30. Fahrleitner-Pammer A, Herberth J, Brown - ing SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res. 2008;23 (11):1850-8.
31. Hamano T, Tomida K, Mikami S, Matsui I, Fujii N, Imai E, et al. Usefulness of bone resorption markers in hemodialysis patients. Bone. 2009;45 (Suppl 1):S19-25.
32. Yano S, Suzuki K, Sumi M, Tokumoto A, Shigeno K, Himeno Y, Sugimoto T. Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism. J Bone Miner Metab. 2010;28(1): 49-54.
33. Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol (Oxf). 2008;69(2):189-96.
34. Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007;65(12 Pt 2):S147-51.
35. Moss DW. Changes in enzyme expression related to differentiation and regulatory factors: the acid phosphatase of osteoclasts and other macrophages. Clin Chim Acta. 1992;209(1-2):131-8.
36. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010;46(7):1223-31.
37. Edwards CJ, Williams E. The role of interleukin- 6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int. 2010;21(8): 1287-93.
38. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93 (9):1483-90.
39. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNFalpha/ IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004;15(1):49-60.
40. Rothe L, Collin-Osdoby P, Chen Y, Sunyer T, Chaudhary L, Tsay A, et al. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology. 1998;139(10):4353-63.
41. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003;33(1):28-37.
42. Tuan RS, Lee FY, Konttinen YT, Wilkinson JM, Smith RL. What are the local and systemic biologic reactions and mediators to wear debris, and what host factors determine or modulate the biologic response to wear particles? J Am Acad Orthop Surg. 2008;16 (Suppl 1):S42-8.
43. Yano S, Mentaverri R, Kanuparthi D, Bandyopadhyay S, Rivera A, Brown EM, Chattopadhyay N. Functional expression of beta-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts. Endocrinol - ogy. 2005;146(5):2324-35.
44. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res. 2004;19(12):2065-77.
45. Andrade I Jr, Taddei SR, Garlet GP, Garlet TP, Teixeira AL, Silva TA, Teixeira MM. CCR5 down-regulates osteoclast function in orthodontic tooth movement. J Dent Res. 2009;88(11):1037-41.
46. Bon JM, Zhang Y, Duncan SR, Pilewski JM, Zaldonis D, Zeevi A, et al. Plasma inflammatory mediators associated with bone metabolism in COPD. COPD. 2010;7(3): 186-91.
47. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-95.
48. Anderson D, Macnee W. Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obstruct Pulmon Dis. 2009;4:(2)321-35.
49. Caplan-Shaw CE, Arcasoy SM, Shane E, Lederer DJ, Wilt JS, O'Shea MK, et al. Osteoporosis in diffuse parenchymal lung disease. Chest. 2006;129(1):140-6.
50. Tschopp O, Schmid C, Speich R, Seifert B, Russi EW, Boehler A. Pretransplantation bone disease in patients with primary pulmonary hypertension. Chest. 2006;129(4): 1002-8.
51. Sundaram N, Tailor A, Mendelsohn L, Wansapura J, Wang X, Higashimoto T, et al. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood. 2010;116(1):109-12.
52. Robbins IM, Barst RJ, Rubin LJ, Gaine SP, Price PV, Morrow JD, Christman BW. Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension. Chest. 2001;120(5):1639-44.